Ocugen Inc. (OCGN)
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar - Chief Medical Officer Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Shankar Musunuri - Co-Founder, CEO & Chairman Tiffany J. Hamilton - AVP & Head of Corporate Communications Conference Call Participants Boris Peaker - Unidentified Company Daniil V.
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
Ocugen: Three Potential Gene-Therapy Filings By 2028
Ocugen's OCU400 Phase 3 plus Korean licensing underpin potential 2026 BLA remains the company's best bet at its first commercial gene therapy revenue. OCU410ST also received a Rare Pediatric Disease status and now heads towards a pivotal Phase 2/3 trial. Its potential approval would also give OCGN a valuable PRV. OCU410 has shown promising early vision-gain and lesion-slow data, which could be a third BLA target by 2028.
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Call Start: 8:30 January 1, 0000 8:59 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2025 - Earnings Conference Call May 9, 2025, 8:00 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Arun Upadhyay - Chief Scientific Office Conference Call Participants Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to Ocugen's First Quarter 2025 financial results and business update.
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Ocugen, Inc. (NASDAQ:OCGN ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Operator Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript
Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3
Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 has received the FDA's RMAT designation and is supported by an Expanded Access Program. Ocugen's broader pipeline includes OCU410 for geographic atrophy and OCU410ST for Stargardt disease, both progressing through early trials.
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
OCGN receives Health Canada's No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
Ocugen's most advanced product candidate, OCU400, has started Phase 3 clinical trials, aiming for regulatory approval in the U.S. and Europe by 2026. The gene therapy platform shows promise in treating retinal diseases, with potential to become a market leader in RP if successful. Despite financial struggles, Ocugen's gene therapy products have high potential, supporting a speculative "Buy" rating for long-term investors with a high risk tolerance.
Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year?
Here is how Ocugen (OCGN) and Organon (OGN) have performed compared to their sector so far this year.
FINAL OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / June 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Ocugen securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period").
